Table 2.
Selected maternal and infant outcomes during hospitalization (during pregnancy or in the post-partum period) between March 2020 and March 2023.
| All Pregnancies n = 524 (%) |
SARS-CoV-2 Positive n = 275 (%) |
SARS-CoV-2 Negative n = 249 (%) |
p-Value a | |
|---|---|---|---|---|
| Hypertensive disorders in pregnancy | 171 (32.6) | 82 (29.8) | 89 (35.7) | 0.149 c |
| Postpartum hemorrhage | 73 (13.9) | 36 (13.1) | 37 (14.9) | 0.559 c |
| Maternal sepsis | 23 (4.4) | 11 (4.0) | 12 (4.8) | 0.648 c |
| Gestational age at time of delivery (n = 532) | ||||
| <37 weeks | 130 (24.8) | 72 (27.6) | 58 (24.0) | 0.354 b |
| 37–41 weeks | 373 (71.2) | 189 (72.4) | 184 (76.0) | |
| Birth outcomes (n = 553) | ||||
| Stillbirths’ | 11 (2.1) | 6 (2.2) | 5 (2.0) | 0.407 b |
| Miscarriages (<20 weeks) | 21 (4.0) | 14 (5.1) | 7 (2.8) | |
| Live birth | 492 (93.9) | 255 (92.7) | 237 (95.2) | |
| Maternal outcomes | ||||
| ICU admission (yes/no) | 35 (6.7) | 24 (8.7) | 11 (4.4) | 0.048 c |
| Ventilator support | ||||
| No support | 402 (76.7) | 199 (72.4) | 203 (81.5) | 0.005 b |
| Non-invasive | 93 (17.7) | 52 (18.9) | 41 (16.5) | |
| Invasive | 26 (5.0) | 22 (8.0) | 4 (1.6) | |
| Maternal Death | 5 (1.0) | 4 (1.5) | 1 (0.4) | 0.216 c |
| Neonatal outcomes | ||||
| Fetal sex (n = 515) | ||||
| Male | 279 (54.2) | 143 (53.4) | 136 (55.1) | 0.698 b |
| Female | 236 (45.8) | 125 (46.6) | 111 (44.9) | |
| NICU-admission (n = 503) | 157 (31.2) | 93 (35.6) | 64 (26.5) | 0.026 c |
| Neonatal Respiratory Distress (n = 503) | 123 (25.1) | 68 (26.1) | 58 (23.9) | 0.589 c |
| Size for gestational age (n = 499) | ||||
| Appropriate growth | 380 (76.2) | 200 (77.5) | 180 (74.7) | 0.458 b |
| SGA/LGA | 119 (23.8) | 58 (22.5) | 61 (25.3) | |
a. Bivariate associations between selected maternal and infant outcomes with SARS-CoV-2 infection were assessed through Chi-square tests of independence. b. Comparisons conducted among categorical variable (i.e., belongs to one of the groups) distributions of SARS-CoV-2 exposed group versus non-exposed groups. c. Comparisons conducted between dichotomous variable (i.e., no versus yes for the characteristic) distributions of SARS-CoV-2 exposed group versus non-exposed groups.